首页> 外文期刊>Nuclear Medicine and Biology >An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo(6.6.6)icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals.
【24h】

An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo(6.6.6)icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals.

机译:新型笼状双功能螯合剂4-((8-氨基-3,6,10,13,16,19-六氮杂双环(6.6.6)二十烷-1-基氨基)甲基)苯甲酸的改进的合成和生物学评价酸,用于64Cu放射性药物。

获取原文
获取原文并翻译 | 示例
       

摘要

INTRODUCTION: Stable attachment of (64)Cu(2+) to a targeting molecule usually requires the use of a bifunctional chelator (BFC). Sarcophagine (Sar) ligands rapidly coordinate (64)Cu(2+) within the multiple macrocyclic rings comprising the cage structure under mild conditions, providing high stability in vivo. Previously, we have designed a new versatile cage-like BFC Sar ligand, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid (AmBaSar), for (64)Cu radiopharmaceuticals. Here we report the improved synthesis of AmBaSar, (64)Cu(2+) labeling conditions and its biological evaluation compared with the known BFC 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA). METHODS: The AmBaSar was synthesized in four steps starting from (1,8-diamine-Sar) cobalt(III) pentachloride ([Co(DiAmSar)]Cl(5)) using an improved synthetic method. The AmBaSar was labeled with (64)Cu(2+) in pH 5.0 ammonium acetate buffer solution at room temperature, followed by analysis and purification with HPLC. The in vitro stability of (64)Cu-AmBaSar complex was evaluated in phosphate buffered saline (PBS), fetal bovine serum and mouse blood. The microPET imaging and biodistribution studies of (64)Cu-AmBaSar were performed in Balb/c mice, and the results were compared with (64)Cu-DOTA. RESULTS: The AmBaSar was readily prepared and characterized by MS and (1)H NMR. The radiochemical yield of (64)Cu-AmBaSar was >or=98% after 30 min of incubation at 25 degrees C. The (64)Cu-AmBaSar complex was analyzed and purified by HPLC with a retention time of 17.9 min. The radiochemical purity of (64)Cu-AmBaSar was more than 97% after 26 h of incubation in PBS or serum. The biological evaluation of (64)Cu-AmBaSar in normal mouse demonstrated renal clearance as the primary mode of excretion, with improved stability in vivo compared to (64)Cu-DOTA. CONCLUSIONS: The new cage-like BFC AmBaSar was prepared using a simplified synthetic method. The (64)Cu-AmBaSar complex could be obtained rapidly with high radiochemical yield (>/=98%) under mild conditions. In vitro and in vivo evaluation of AmBaSar demonstrated its promising potential for preparation of (64)Cu radiopharmaceuticals.
机译:简介:(64)Cu(2+)与目标分子的稳定连接通常需要使用双功能螯合剂(BFC)。石棺(Sar)配体可在温和条件下快速协调包含笼结构的多个大环内的(64)Cu(2+),在体内提供高稳定性。以前,我们已经设计了一种新型的通用笼状BFC Sar配体,4-((8-氨基-3,6,10,13,16,19-六氮杂双环[6.6.6]二十烷-1-基氨基)甲基)苯甲酸酸(AmBaSar),用于(64)Cu放射性药物。在这里,我们报告与已知的BFC 1,4,7,10-四氮杂环十二烷-N,N',N'',N''相比,改进的AmBaSar,(64)Cu(2+)标记条件的合成及其生物学评估'-四乙酸(DOTA)。方法:采用改进的合成方法,从(1,8-二胺-Sar)五氯化钴(III)([Co(DiAmSar)] Cl(5))开始,分四个步骤合成AmBaSar。室温下,在pH 5.0的乙酸铵缓冲溶液中,用(64)Cu(2+)标记AmBaSar,然后进行分析和HPLC纯化。在磷酸盐缓冲液(PBS),胎牛血清和小鼠血液中评估了(64)Cu-AmBaSar复合物的体外稳定性。在Balb / c小鼠中进行了(64)Cu-AmBaSar的microPET成像和生物分布研究,并将结果与​​(64)Cu-DOTA进行了比较。结果:AmBaSar易于制备,并通过MS和(1)H NMR表征。在(25°C)孵育30分钟后(64)Cu-AmBaSar的放射化学收率≥98%。(64)Cu-AmBaSar复合物通过HPLC分析和纯化,保留时间为17.9分钟。在PBS或血清中孵育26小时后,(64)Cu-AmBaSar的放射化学纯度超过97%。在正常小鼠中对(64)Cu-AmBaSar的生物学评估表明,肾脏清除是排泄的主要方式,与(64)Cu-DOTA相比,其体内稳定性更高。结论:采用简化的合成方法制备了新型笼状BFC AmBaSar。 (64)Cu-AmBaSar复合物可以在温和的条件下以高放射化学收率(> = 98%)快速获得。 AmBaSar的体外和体内评估证明了其制备(64)Cu放射性药物的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号